反应详情

To a solution of N-({3-[(3-bromo-5-chlorophenyl)oxy]-4-chloro-2-fluorophenyl}methyl)-4-chloro-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazole-5-carboxamide (120 mg, 0.192 mmol) in DCM (5 ml) was added TFA (1.0 mL) and the mixture was stirred at room temperature for 3 hours. The solvent was removed and the crude material was purified via reverse phase HPLC to give N-({3-[(3-bromo-5-chlorophenyl)oxy]-4-chloro-2-fluorophenyl}methyl)-4-chloro-1H-imidazole-5-carboxamide (78 mg, 0.158 mmol, 82% yield). 1H NMR (400 MHz, DMSO-d6) δ ppm 13.12 (d, 1H), 8.02-8.42 (m, 1H), 7.73 (s, 1H), 7.41-7.54 (m, 1H), 7.32 (t, 1H), 7.08-7.15 (m, 1H), 6.95-7.06 (m, 1H), 4.49 (d, 2H). LC-MS (ES+) m/z 491.87, [M+H].

1. customThe solvent was removed
2. customthe crude material was purified via reverse phase HPLC